Mustgrow Biologics Corp. ( (MGROF) ) has released its Q3 earnings. Here is a breakdown of the information Mustgrow Biologics Corp. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MustGrow Biologics Corp., a leader in biological and regenerative agriculture solutions, offers innovative eco-friendly alternatives to synthetic chemicals and fertilizers, focusing on sustainable farming practices.
In its latest earnings report for Q3-2025, MustGrow Biologics Corp. announced a record sales revenue of $0.8 million, marking a significant improvement from the previous year with no recorded revenue. The company also reported a gross profit of $180,555, reflecting a gross profit margin of 22.9%, up from 20.9% in the previous quarter.
The company attributes its improved financial performance to higher margin product sales through its Canadian sales and distribution division, NexusBioAg. MustGrow’s strategic focus remains on expanding its NexusBioAg business and TerraSante biofertility product sales in the U.S., aiming to capitalize on the traditionally stronger sales periods in Q1 and Q4.
With $3.3 million in cash and equivalents and $1.9 million in inventory as of September 30, 2025, MustGrow is well-positioned to continue its growth trajectory. The company remains committed to driving shareholder value through the commercialization of its intellectual property portfolio and expanding its product lines.
Looking ahead, MustGrow’s management is optimistic about the upcoming quarters, anticipating strong sales as Canadian farmers prepare for the 2026 growing season. The company continues to focus on sustainable agriculture solutions, aiming to replace banned or restricted synthetic chemicals with its innovative products.